King Valerie J, Viswanathan Meera, Bordley W Clayton, Jackman Anne M, Sutton Sonya F, Lohr Kathleen N, Carey Timothy S
Cecil B. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, 725 Airport Road, Campus Box 7590, Chapel Hill, NC 27599-7595, USA.
Arch Pediatr Adolesc Med. 2004 Feb;158(2):127-37. doi: 10.1001/archpedi.158.2.127.
Bronchiolitis is the most common lower respiratory tract infection in infants. Up to 3% of all children in their first year of life are hospitalized with bronchiolitis. Bronchodilators and corticosteroids are commonly used treatments, but little consensus exists about optimal management strategies.
To conduct a systematic review of the effectiveness of commonly used treatments for bronchiolitis in infants and children.
We searched MEDLINE and the Cochrane Controlled Trials Register for references to randomized controlled trials of bronchiolitis treatment published since 1980.
Randomized controlled trials of interventions for bronchiolitis in infants and children were included if they were published in English between 1980 and November 2002 and had a minimum sample size of 10.
We abstracted data on characteristics of the study population, interventions used, and results of studies meeting entry criteria into evidence tables and analyzed them by drug category.
Interventions were grouped by drug category and qualitatively synthesized.
Of 797 abstracts identified in the literature search, we included 54 randomized controlled trials. This review includes 44 studies of the most common interventions: epinephrine (n = 8), beta2-agonist bronchodilators (n = 13), corticosteroids (n = 13), and ribavirin (n = 10). Studies were, in general, underpowered to detect statistically significant outcome differences between study groups. Few studies collected data on outcomes that are of great importance to parents and clinicians, such as the need for and duration of hospitalization.
Overall, little evidence supports a routine role for any of these drugs in treating patients with bronchiolitis. A sufficiently large, well-designed pragmatic trial of the commonly used interventions for bronchiolitis is needed to determine the most effective treatment strategies for managing this condition.
细支气管炎是婴儿最常见的下呼吸道感染。在一岁以内的儿童中,高达3%的儿童因细支气管炎住院治疗。支气管扩张剂和皮质类固醇是常用的治疗方法,但对于最佳管理策略几乎没有共识。
对婴儿和儿童细支气管炎常用治疗方法的有效性进行系统评价。
我们检索了MEDLINE和Cochrane对照试验注册库,以查找自1980年以来发表的关于细支气管炎治疗的随机对照试验的参考文献。
纳入1980年至2002年11月期间以英文发表、样本量至少为10的婴儿和儿童细支气管炎干预措施随机对照试验。
我们将符合纳入标准的研究的研究人群特征、所用干预措施和研究结果的数据提取到证据表中,并按药物类别进行分析。
干预措施按药物类别分组并进行定性综合。
在文献检索中识别出的797篇摘要中,我们纳入了54项随机对照试验。本综述包括44项关于最常见干预措施的研究:肾上腺素(n = 8)、β2受体激动剂支气管扩张剂(n = 13)、皮质类固醇(n = 13)和利巴韦林(n = 10)。总体而言,这些研究的样本量不足以检测出研究组之间在统计学上有显著意义的结果差异。很少有研究收集对家长和临床医生非常重要的结果数据,如住院需求和住院时间。
总体而言,几乎没有证据支持这些药物中的任何一种在治疗细支气管炎患者方面的常规作用。需要进行一项足够大、设计良好的关于细支气管炎常用干预措施的实用试验,以确定管理这种疾病的最有效治疗策略。